SAFETY DATA SHEETS

This SDS packet was issued with item: 078944924

N/A



Section 1. Identification

Common/Trade name	: [Desmopressin Nasal Spray Solu	tion USP, 0.01%		
Recommended use		Pharmaceutical industry: Dosage form Therapeutic category: Antiduretic			
	a n	associated with this product. It is to be used	to inform workers of the safety, health and environmental information d by people handling the material within the workplace only. It is not atients should consult with their physician, pharmacist or the information		
Recommended restrictions	: N	No other uses are advised.			
Supplier	- 1 Τ Ν	Canada Apotex Inc. 50 Signet Drive Foronto, Ontario M9L 1T9 I16-749-9300	U.S. Apotex Corp. 2400 N. Commerce Parkway Suite 400 Weston, FLA 33326 Telephone: (954)384-8007 Toll Free: 1-800-706-5575		
Emergency phone	+ F	United States/Canada (Chemtrec) 1- +1 703-527-3887 (24 hours) For general information call: I-(416)-749-9300 ext. 8483 (8 AM-4			
Section 2. Hazar	ds	dentification			
Classification of the substance or mixture		products (drugs) when it is in the solid, f	cording to Article 1, item 5 a) of CLP Regulation (EC) 1272/2008, medicinal inal form for direct administration to the patient or are packaged by the retail establishment are exempt from the requirements of classification,		
GHS label element	S	: Exempt from requirements.			
Hazards not otherwise classified		: Exempt from requirements.			
Section 2 Com	n	sition/Information on Ingredi	onte		

Section 3. Composition/Information on Ingredients		
CAS #	% (w/w)	
62357-86-2	0.01	
8001-54-5	<1	
7782-85-6	<1	
7647-14-5	<1	
77-92-9	<1	
	CAS # 62357-86-2 8001-54-5 7782-85-6 7647-14-5	

Specific chemical identity and/or percentage of composition has been withheld as a trade secret.

Chemical name:Not applicable.Synonyms:Not available.Chemical family:Cyclic polypeptideMolecular
weight:Not applicable.

Continued on Next Page

Revision date: 7/14/2017

Chemical

Not applicable.

formula

Section 4. Firs	st Aid Measures
Eye contact	: Flush with copious quantities of water. If irritation persists, obtain medical advice.
Skin contact	: Flush with copious amounts of water. Seek medical attention if irritation persist.
Inhalation	: Remove from exposure. Persons developing serious hypersensitivity reactions must receive immediate medical attention. If not breathing give artificial respiration. If breathing is difficult give oxygen.
Ingestion	: Never give anything by mouth if victim is losing consciousness, or is unconscious or convulsing. Rinse mouth thoroughly with water. If breathing is difficult, give oxygen. If breathing has stopped, trained personnel should begin artificial respiration, or if the heart has stopped, cardiopulmonary resuscitation (CPR) immediately. Seek medical attention.
Potential acute and delayed health effects	: Refer to Sec. 11

Section 5. Fire Fighting Measures

Specific hazard arising from the chemical	:	During fire, gases hazardous to health may be formed.
Suitable extinguishing media and special protective equipment for firefighters	:	Extinguisher media: Use extinguishing media suitable for surrounding materials. Special fire fighting procedures: As with all fires, evacuate personnel to safe area. Firefighters should use self- contained breathing equipment and protective clothing.

Section 6. Accidental Release Measures			
Methods and materials for containment and cleaning up	: Assess hazard levels. Contain and clean up spillage and place into an appropriate labeled waste disposal container. Avoid generating dust or aerosols. Wash spill surface using appropriate cleaning solutions. Should clothing be contaminated, wash before reuse.		
Protective equipment and personal precautions	: Keep unnecessary personnel away. Wear appropriate personal protective equipment.		
Section 7. Hand	Section 7. Handling and Storage		

Precautions for safe handling	: Avoid contact with eyes.
Conditions for safe storage	: Store at 25°C (77°F) [see USP Controlled Room Temperature]; excursions permitted to 15-30°C (59-86°F). Store bottles in upright position.

Section 8. Exposure Controls/Personal Protection

Engineering :	General room ventilation. Local exhaust ventilation and/or process enclosures where applicable. Fume hoods where
Controls	available. Additional respiratory protection is not required when working in a fume hood.

 Desmopressin Nasal Spray Solution USP, 0.01%
 Page Number: 3

 Personal Protection
 : Skin: Lab coat

 Respiratory: Under normal work conditions, the use of respiratory protective equipment is not expected to be required. If the physical state of the finished product is altered by crushing, grinding or breakage or for spill cleaning, an approved NIOSH respirator may be required.

 Hand: Nitrile gloves
 Eye: Safety glasses

 Occupational exposure limits
 : Not established.

Section 9. Physical and Chemical Properties

Physical state and appearance	: Solution	
рН	Not available.	Odor : Not available.
Melting point/ Freezing point	: Not available.	Odor threshold : Not available.
Boiling point	: Not available.	Conditions of : No additional remark. instability
Volatility	: Not available.	Decompositon : Not available. temperature
Specific gravity	: Not available.	Partition : Not available. Coefficient:
Evaporation rate	Not available.	Viscosity : Not available.
Vapor density	Not available.	Flash points : Not applicable.
Relative density	Not available.	Flammable limits : Not applicable.
Vapor pressure	: Not available.	Autoignition : Not applicable. temperature
Flammability	Not flammable.	
Solubility	Soluble in water.	

Section 10. Stability and Reactivity

Reactivity	Not available.
Chemical Stability	: The product is stable.
Possibility of hazardous reactions	: Not available.
Hazardous decomp. products	: When heated to decomposition material emits toxic fumes.
Incompatible materials/ Conditions to avoid	: Protect from heat.

Continued on Next Page

Revision date: 7/14/2017

Section 11. Toxicological Information

Information on the likely routes of exposure	:	Inhalation. Eye contact.
Toxicity data	:	Desmopressin acetate: RTECS#: YW9000000 LDLo: 891 ng/kg/1D-I (intravenous -man) LD50: >2 mg/kg (intravenous-rat)
Delayed and immediate effects and also chronic effects from short and long term exposure	:	 Specific target organ toxicity - repeated exposure: May cause damage to organs (kidney) through prolonged or repeated exposure. Carcinogenicity: Not listed as carcinogen by IARC, NTP, ACGIH, or OSHA. Reproductive Toxicity: No information available. Teratogenicity: Category B: Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 µg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m²) revealed no harm to the fetus due to DDAVP (desmopressin acetate). There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Mutagenicity: No information available. Remark
		Not available.
Symptoms related to the physical, chemical and toxicological characteristics	:	Adverse effects: high dosages of intranasal Desmopressin acetate have produced transient headache and nausea. Nasal congestion, rhinitis and flushing have also been reported occasionally along with mild abdominal cramps. These symptoms disappeared with reduction in dosage. Nosebleed, sore throat, cough and upper respiratory infections have also been reported.

Section 12. Ecological Information

Ecotoxicity	: Not available.
Persistence and degradability	• Not available.
Bioaccumulative potential	: Not available.
Mobility in soil	Not available.
Other adverse effects	: Not available.

Section 13. Disposal Considerations

Waste Disposal

: Follow all appropriate safe work procedures and local regulations for disposal. Use only licensed disposal and waste hauling companies.

Desmopressin Nasal Spray Solution USP, 0.01%

Regulatory information	UN number	Proper shipping name	Class	Packing group	Additional information
TDG- road Canada/U.S.			Not regulated.		
ICAO/IATA			Not regulated.		
IMDG Class			Not regulated.		
Section 1	5. Regula	atory Information	1	1	
Canada Regulations		No additional remark.			
Podulation					

Other Regulations : Not available.

Section 16. Other Information

- References
- : RTECS Database RxList Monographs Apotex Product Monograph U.S. Pharmacopeia

7/14/2017

Revision date:

Notice to Reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.